共 72 条
[1]
Kovesdy CP(2014)Management of hyperkalaemia in chronic kidney disease Nat Rev Nephrol 10 653-662
[2]
Montford JR(2017)How dangerous is hyperkalemia? J Am Soc Nephrol 28 3155-3165
[3]
Linas S(2017)Managing hyperkalemia in high-risk patients in long-term care Am J Manag Care 23 S27-S36
[4]
Kumar R(2017)The cost of hyperkalemia in the United States Kidney Int Rep 14 385-393
[5]
Kanev L(2019)The economic implications of hyperkalemia in a Medicaid managed care population Am Health Drug Benefits 12 352-361
[6]
Woods SD(2007)Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program J Am Coll Cardiol 50 1959-1966
[7]
Betts KA(2021)Healthcare resource utilization and costs associated with hyperkalemia in a large managed care population J Pharm Health Serv Res 12 35-41
[8]
Woolley JM(2013)Long-term care services in the United States: 2013 overview Vital Health Stat 3 1-107
[9]
Mu F(2021)2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC Eur Heart J. 42 3599-3726
[10]
Desai NR(2011)Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena Kidney Int Suppl 2016 20-28